Trial Profile
A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 1399686 (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2011 Planned end date changed from 1 Dec 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 03 Dec 2010 Additional location (Canada) added as reported by ClinicalTrials.gov.